Why Hims & Hers Health, Inc. (HIMS) stock moved
Hims & Hers Health, Inc. (HIMS) shares tumbled 8.9% to $28.84 as of August 30, 2026, a significant decline from the prior close of $31.66. BestStocks flagged the session as a major change for HIMS. Below, we break down what changed for HIMS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
HIMS fell 8.9% to $28.84
HIMS tumbled 8.9% in its latest session, moving from $31.66 to $28.84.
What it means for Hims & Hers Health, Inc. investors
For Hims & Hers Health, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Hims & Hers Health bounced +6.92% to $31.89 on reports of a potential partnership with weight-loss drug maker Novo Nordisk to distribute branded products on its platform, according to web sources; Hims & Hers Health, Inc. (HIMS) moved +5.75% from $35.15 to $37.17 on 2026-07-15. Weighing against that: Material negative event; Sharp 8.9% decline — elevated risk. Wall Street's consensus price target sits at $30.20, implying +4.7% upside from $28.84. BestStocks rates the overall signal quality low (57/100). With earnings roughly 71 days out, the next report is the most likely near-term test of the move.
HIMS price reaction
HIMS last traded at $28.84, down $2.82 (-8.91%) from the previous close of $31.66. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $27.04 and $33.78, and it currently sits about 27% of the way up that band.
Bullish and bearish analyst opinions on Hims & Hers Health, Inc. (HIMS)
The consensus analyst price target on Hims & Hers Health, Inc. (HIMS) is $30.20, 4.7% above the recent $28.84. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HIMS line up.
The bullish case
- Wall Street's consensus price target of $30.20 implies +4.7% upside from $28.84.
- The Street's most bullish target is $42.00 (+45.6%).
- Hims & Hers Health bounced +6.92% to $31.89 on reports of a potential partnership with weight-loss drug maker Novo Nordisk to distribute branded products on its platform, according to web sources.
- Hims & Hers Health, Inc. (HIMS) moved +5.75% from $35.15 to $37.17 on 2026-07-15.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $12.50 (-56.7%).
- Material negative event.
- Sharp 8.9% decline — elevated risk.
- Hims & Hers Health (HIMS) declined 6.41% to $29.63 intraday, cited by Google's AI Overview as linked to content on finance.yahoo.com covering the stock's move on 2026-08-28.
- Hims & Hers shares fell 6.05% to $29.83, continuing a sharp year-to-date decline of 15.9% (per Yahoo Finance, Apr 29, 2026).
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for HIMS
In-depth HIMS event analyses
Frequently asked questions about HIMS
Why did Hims & Hers Health, Inc. (HIMS) stock move?
HIMS tumbled 8.9% to $28.84. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did HIMS stock fall?
HIMS lost 8.91% ($2.82) versus the prior close of $31.66, last trading at $28.84 on 0.8× average volume.
When is Hims & Hers Health, Inc.'s next earnings date?
HIMS's next earnings report is estimated for 2026-11-09 — about 71 days away.
What is the analyst price target for HIMS?
The consensus analyst price target for HIMS is $30.20, about 4.7% above the current $28.84. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.
How BestStocks tracks HIMS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared HIMS-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for HIMS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.